Detalhe da pesquisa
1.
Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial.
Haematologica
; 108(7): 1827-1839, 2023 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36200421
2.
Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma.
Haematologica
; 107(10): 2395-2407, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35354252
3.
How we approach: Severe congenital neutropenia and myelofibrosis due to mutations in VPS45.
Pediatr Blood Cancer
; 66(1): e27473, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30294941
4.
Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed/refractory multiple myeloma.
Blood Adv
; 2024 May 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38768428
5.
Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma.
J Clin Oncol
; 42(14): 1665-1675, 2024 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38358946
6.
Clonal Myeloid Dysplasia Following CAR T-Cell Therapy: Chicken or the Egg?
Cancers (Basel)
; 15(13)2023 Jul 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37444582
7.
Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis.
Clin Cancer Res
; 28(23): 5156-5166, 2022 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36107221
8.
Specific antibody deficiency and autoinflammatory disease extend the clinical and immunological spectrum of heterozygous NFKB1 loss-of-function mutations in humans.
Haematologica
; 101(10): e392-e396, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27365489
9.
A human case of GIMAP6 deficiency: a novel primary immune deficiency.
Eur J Hum Genet
; 29(4): 657-662, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33328581
10.
CD44 involvement in autoimmune inflammations: the lesson to be learned from CD44-targeting by antibody or from knockout mice.
Ann N Y Acad Sci
; 1110: 233-47, 2007 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-17911438
11.
miR-103 inhibits proliferation and sensitizes hemopoietic tumor cells for glucocorticoid-induced apoptosis.
Oncotarget
; 8(1): 472-489, 2017 Jan 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27888798
12.
Can CD44 Be a Mediator of Cell Destruction? The Challenge of Type 1 Diabetes.
PLoS One
; 10(12): e0143589, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26624007